Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

27 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials led

Ongoing

1,382

Total enrollment

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1

Phase 2

Not applicable

Trials by status

Completed

Terminated

Trials led

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)Alzheimer's diseasePh 2Completed229

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy SubjectsAge 18-45Ph 1Completed80

Study GSI-136 in Healthy Young and Healthy Elderly SubjectsHealthy volunteersPh 1Completed80

Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers DiseaseAlzheimer's diseasePh 1Completed80

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly SubjectsAge ≥18Ph 1Completed80

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese MalesAge 20-45Ph 1Completed72

Study Evaluating Safety of GSI 136 in Young and Elderly Japanese MalesAge ≥20Ph 1Completed72

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed72

Single Ascending Dose Study of SRA-444 in Healthy SubjectsAge 18-50Ph 1Completed64

Study Evaluating PAZ-417 in Healthy Young/ElderlyHealthy volunteersN/ACompleted56

Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy AdultsAge 18-45Ph 1Completed56

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315Healthy volunteersPh 1Terminated56

Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsAge ≥20Ph 1Completed56

Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531Age 18-65Ph 1Completed56

Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor OccupancyAge ≥60Ph 1Completed42

Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy SubjectsHealthy volunteersPh 1Completed40

Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly SubjectsAge ≥18Ph 1Completed40

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531Age ≥20Ph 1Completed32

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese MalesAge 20-45Ph 1Completed32

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789Healthy volunteersPh 1Completed24

Study Evaluating GSI-953 in Healthy Young and Alzheimer's PatientsHealthy volunteersPh 1Completed17

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)Alzheimer's diseasePh 2Completed16

Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-AdministeredAge 18-55Ph 1Completed14

Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's DiseaseAlzheimer's diseasePh 1Terminated10

Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male SubjectsAge 18-50Ph 1Completed6

Study Evaluating the Effect of Lecozotan SR on the QTc IntervalAge 18-55Ph 1Completednot disclosed

Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and DigoxinAge 18-55Ph 1Completednot disclosed